Atara brings on Novartis vet to replace founder Ciechanover as chief
After founding T-cell immunotherapy company Atara Biotherapeutics using Amgen $AMGN drug assets in 2012, Isaac Ciechanover made a surprise decision to leave the company this January. Novartis veteran Pascal Touchon is set to replace him as chief, the South San Francisco biotech said on Tuesday.
Existing CAR-T therapies — Novartis’ $GILD Kymriah and Gilead’s $GILD Yescarta — target a single antigen called CD19. Atara — akin to other players in pursuit of next-gen CAR-T drugs — is working on engineering T cells (a type of white blood cell) to tackle multiple targets for addressing cancers with diverse cell types that often become resistant to treatment, such as acute myelogenous leukemia and B cell malignancies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.